Urocentrum Praha s.r.o.

Prague 11 trials 4 recruiting

11 Registered trials

4 Currently recruiting

Organisation

Urocentrum Praha s.r.o.

Location

Prague, Czechia

Identifier

ORG-100041056

Address

Karlovo Namesti 319/3, Nove Mesto, 120 00, Czechia

Departments

N/A
NA
Oncology
Onkologie
private center
Urocentrum Praha S.r.o.
Urology

Clinical trials at this site (11)

Search interface

A Study of Abemaciclib (LY2835219) with Abiraterone in Men with Prostate Cancer that has Spread to Other Parts of the Body and is Expected t… Recruiting

2022-500461-28-06 High-Risk Metastatic Hormone-Sensitive Prostate Cancer 5 2022-09-15
A Study to Learn About the Investigational Medicine Called Mevrometostat (PF-06821497) in Men With Metastatic Castration-Sensitive Prostate … Recruiting

2024-519369-24-00 METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER 5 2026-01-29
A Phase 3 Study Comparing BMS-986365 versus Investigator’s Choice of Therapy in Participants with Metastatic Castration-resistant Prostate C… Recruiting

2024-517422-25-00 Metastatic Castration-resistant Prostate Cancer (mCRPC) 5 2025-05-22
C2321003: A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men with Metastatic Castration-Resistant… Recruiting

2024-511652-40-00 METASTATIC CASTRATION RESISTANT PROSTATE CANCER 5 2025-02-05
Apalutamide, Radiotherapy and LHRH Agonist in High-Risk Hormone-Sensitive Prostate Cancer Patients Assessed by PSMA-PET Ended

2023-505852-23-00 High risk recurrent prostate cancer previously treated 5 2020-11-12
An open study for participants who have been on darolutamide treatment in any other Bayer study Ended

2022-502084-38-00 Cancer 5 2020-10-16
Study of Cabozantinib in Combination With Atezolizumab compared to Second Novel Hormonal Therapy (NHT) in Subjects with Metastatic Castratio… Ended

2024-516481-11-00 Metastatic Castration-Resistant Prostate Cancer 5 2020-09-22
Capivasertib + Abiraterone as Treatment for Patients with Metastatic Hormone-sensitive Prostate Cancer Characterised by PTEN deficiency (CAP… Ended

2023-504998-20-00 Metastatic Hormone-sensitive Prostate Cancer Characteri 5 2020-09-18
Investigation of Radium-223 dichloride (Xofigo), a treatment that gives off radiation that helps kill cancer cells, compared to a treatment … Ended

2023-505830-89-00 metastatic castrate resistant prostate cancer (mCRPC) 6 2020-08-05
Study on Olaparib Plus Abiraterone as First-line Therapy in Men with Metastatic Castration-resistant Prostate Cancer Ended

2024-511144-86-00 Metastatic castration-resistant prostate cancer 5 2019-02-14
A Clinical study to assess the safety and effectiveness of ARN-509 in men with Castration-Resistant Prostate Cancer (prostate cancer not res… Ended

2023-509221-47-00 Castration-Resistant Prostate Cancer 5 2014-02-12